ArticleBMC public health2025
Global, regional, and national epidemiology of cervical cancer in elderly women from 1990 to 2021 and its prediction to 2035.
Article in BMC public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundCervical cancer among elderly women poses a significant challenge to the elimination of cervical cancer. This study estimated the burden, trends, and disparities of cervical cancer in women aged ≥ 60 years from 1990 to 2021, with projections extending to 2035 at global, regional, and national levels.
methodsDeriving data from Global Burden of Disease Study 2021, we analyzed the incidence, prevalence, and mortality burden of cervical cancer among women aged ≥ 60 years. The average annual percent change calculated by Joinpoint regression analysis was used to demonstrate the temporal trend during 1990–2021. We utilized Spearman correlation analysis to explore relationship between age-standardized rates and socio-demographic index (SDI). A Bayesian age-period-cohort model was applied to forecast burden up to 2035. P < 0.05 was considered statistically significant.
resultsIn 2021, the global age-standardized incidence, prevalence, and mortality rates of cervical cancer among women aged over 60 years were 33.84, 94.02, and 23.87 per 100,000 population, respectively. The proportion of deaths among seniors with cervical cancer relative to the total number of cervical cancer cases steadily increased, rising from 42% in 1990 to over 47% in 2021. The overall age-standardized rate decreased with rising SDI. The most significant declines in incidence and mortality rates were seen in Australasia, while substantial increases were found in Southern Sub-Saharan Africa. By 2035, the number of deaths among seniors is projected to reach 176,000, increasing from 139,800 in 2021, with age-standardized mortality rate of 20.3 per 100,000 population in 2035. The age-standardized prevalence rate will rise to 103.85 per 100,000 population, while incidence and mortality rates are predicted to continue declining.
conclusionThis study is the first to analyze the burden of cervical cancer among elderly women by using age-specific epidemiological data from the GBD 2021. It highlights the increasing disease burden and significant socioeconomic disparities in this population, warranting further investigation. Policymakers and healthcare providers should prioritize the needs of seniors to combat cervical cancer.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.